Starship Orbit Success Intensifies Pressure on Rocket Lab's Neutron Bet

What happened

SpaceX's Starship reaching orbit scrambles launch economics, directly threatening Rocket Lab's medium-lift Neutron program. Rocket Lab's Q2 2026 revenue rose 62% to $234.1M and backlog hit $2.36B, but the stock already prices in aggressive Neutron success. Management's latest milestone is only pad delivery in Q4 2026, with first launch possibly slipping to 2027 after the January tank failure. The Iridium acquisition compounds risk through dilution, pushing shares outstanding from 513.0M to 578.9M. Against this backdrop, Redwire's infrastructure focus may be better insulated, undermining Rocket Lab's launch-centric strategy.

Implication

Investors should treat the Starship milestone as a negative catalyst that raises the execution bar for Neutron. The medium-lift launch market is now more contested, reducing the probability that Neutron achieves the pricing power and demand needed to justify the current $40B market cap. Rocket Lab's strong space systems segment offers some cushion, but the stock's valuation remains dependent on launch success. Near-term, the focus shifts to whether Neutron physically reaches the pad in Q4 2026 and if management can name firm 2027 missions. Until those milestones are met, downside risk outweighs upside potential, supporting a patient approach at lower entry points.

Thesis delta

The Starship orbit milestone reinforces the bearish case by making the medium-lift launch market more competitive, thus lowering the probability of Neutron achieving attractive economics. This increases the risk that Rocket Lab's launch-centric bet underperforms, particularly given the already high expectations embedded in the stock. While the core business remains strong, the risk-reward has deteriorated; our base-case fair value remains $66, but the bear scenario probability rises.